Valuation conundrum of healthcare-related stocks in US and M’sia


THE United States, which is the epicentre of the Covid-19 pandemic, is the base for some of the world’s largest healthcare companies. These companies are in the race to find a vaccine for the virus and have from time to time disclosed the progress of finding a wonder drug to prevent the spread of the virus.

However, the valuations of the more established pharmaceutical companies have remained sober even though the companies are in the forefront of the search to find a vaccine.

Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Salcon unit bags RM9.7mil sewerage deal
Brisk sales for Sunway’s Velocity 3
Scientex to deploy large-scale solar PV system
Velesto poised to see stronger earnings in 2024
Minimal impact forecast for breweries from beer price hike
Wage reform concerns
VSTECS shares hit all-time high
Brahmal is major shareholder of MCE Holdings
Car sales expected to moderate this year
Making ESG accessible to all companies

Others Also Read